NVO

Novo Nordisk A/S (NYSE:NVO) Upgraded by Oddo Bhf to “Outperform”

Source from : Defense World - 1 days ago

Oddo Bhf upgraded shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) from a neutral rating to an outperform rating in a research report released on Thursday, The Fly reports. A number of other ...See details»

Novo Nordisk A/S – Share repurchase programme

Source from : Yahoo - 4 days ago

On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the ...See details»

Allworth Financial LP Acquires 138 Shares of Novo Nordisk A/S (NYSE:NVO)

Source from : Defense World - 3 days ago

Allworth Financial LP grew its stake in shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) by 34.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange ...See details»

Top Analyst Reports for Novo Nordisk, Suncor Energy, & Nasdaq

Source from : YAHOO!Finance - 17 hours ago

Today's Research Daily features new research reports on 12 major stocks, including Novo Nordisk A/S (NVO), Suncor Energy Inc. (SU) and Nasdaq, Inc. (NDAQ).See details»

Ventus and Novo Nordisk enter NLRP3 inhibitor development deal

Source from : Pharmaceutical Technology - 23 hours ago

Ventus Therapeutics and Novo Nordisk have signed a licence agreement for developing peripherally-restricted NLRP3 inhibitor candidates.See details»

Montreal’s Ventus Therapeutics strikes US$700-million-plus deal with pharma giant Novo Nordisk

Source from : The Globe and Mail - 2 days ago

Montreal biotechnology company Ventus Therapeutics Inc. has struck a development and licensing deal with pharma giant Novo Nordisk A/S NVO-N that could be worth more than US$700-million ($960-million) ...See details»

Novo Nordisk grabs NASH drug from Ventus in $703m deal

Source from : pharmaphorum - 1 days ago

Denmark’s Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...See details»

Novo Nordisk pays $70M for a Phase 1-ready cardiometabolic disorder drug

Source from : MedCity News - 1 days ago

Novo Nordisk is acquiring global rights to a Ventus Therapeutics drug candidate with potential applications in cardiometabolic disorders such as NASH and chronic kidney disease. The small molecule ...See details»

Ventus sells its lead drug candidate to Novo Nordisk

Source from : BioPharma Dive - 1 days ago

The biotechnology startup will part with its lead drug candidate, an anti-inflammatory small molecule, in Novo Nordisk’s bet on inflammasome treatments.See details»

Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

Source from : Daily Herald - 2 days ago

Collaboration combines Ventus’ lead NLRP3 inhibitor program with Novo Nordisk’s deep expertise across cardiometabolic diseases Ventus Therapeutics, Inc., a biopharmaceutical company utilizing ...See details»

Foundation behind Novo Nordisk to invest $200M in building quantum research ‘powerhouse’

Source from : BioPharma Dive - 9 days ago

The grant is one of the Novo Nordisk Foundation’s largest and will fund a 12-year research collaboration to construct a quantum computer dedicated to the life sciences.See details»

Ventus Therapeutics cuts $70m deal with Danish drug giant Novo Nordisk

Source from : The Boston Globe on MSN - 2 days ago

The local company is working on drugs to treat conditions such as nonalcoholic fatty liver disease and chronic kidney disease.See details»

Novo Nordisk Foundation investing $200M for first quantum computer for life sciences research

Source from : labiotech - 9 days ago

The Novo Nordisk Foundation has awarded a $200M grant for the first full-scale quantum computer to develop new medicines.See details»

Q&A: Novo Nordisk’s Keith Middleton on its latest DE&I efforts

Source from : MM&M - 8 days ago

How is Novo Nordisk differentiating what it’s doing compared to other players in the space? Middleton: The fact that we work in the therapeutic areas of the diseases that we do, it highlights a huge ...See details»